share_log

RBC Capital Downgrades Avalo Therapeutics to Sector Perform, Lowers Price Target to $0.75

Benzinga ·  Jun 27, 2023 07:42

RBC Capital analyst Gregory Renza downgrades Avalo Therapeutics (NASDAQ:AVTX) from Outperform to Sector Perform and lowers the price target from $9 to $0.75.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment